Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Efgartigimod in Primary immune thrombocytopenia. The expected timing is based on the latest available company guidance and may change.
ADVANCE-(SC) trial. 11/28/23 Top-line data did not meet primary or secondary endpoints. Additional analyses of the dataset are ongoing and the full results will be presented at an upcoming medical meeting. Confirmatory study by end of 2024. 12/15/25:- VYVGART approved for primary immune thrombocytopenia in Japan. 01/12/26:- ADVANCE-NEXT Ph3 primary ITP topline data in Q4 2026 to support U.S. label.
Verification
Confirm timing and program details against the company announcement or filing.